drugset / Trial / NCT05933720
Efficacy and Safety of the Regulatory Polypeptides in Patients With Peripheral Atherosclerosis.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The study is aimed at assessing the role of the activity of markers of endothelial dysfunction (cytotoxic malonic aldehyde (MDA), angiotensin II, endothelial nitric oxide synthase (NO), endothelin-1, prostacyclin) in the systemic circulation in patients with lower extremity atherosclerotic arterial occlusive disease undergoing open reconstructive interventions.
Timeline
- Start
- 2023-04-01
- Primary completion
- 2026-06-01
- Completion
- 2026-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Slavinorm® | Protein / enzyme biologic | 5 mg | Intramuscular |